Pharmacotherapy of obesity in complex diseases

Clin Obes. 2022 Feb;12(1):e12497. doi: 10.1111/cob.12497. Epub 2021 Dec 9.

Abstract

More than 40% of adults in the United States suffer from obesity. Obesity is inextricably linked to many chronic illnesses like type-2 diabetes mellitus, hypertension, hyperlipidemia, heart disease, sleep apnea, stroke, and cancers. When used in combination with lifestyle modifications, pharmacotherapy has a vital role in treating obesity and improves short-term and long-term outcomes. A growing number of physicians are now interested in obesity medicine, and many of them are seeking guidance on how to treat complex patients with co-morbidities. This review provides a practical guide to the use of anti-obesity medications across various obesity-related comorbidities. It provides a general review of the currently approved anti-obesity medications and effective combinations. It discusses the highlights of the major trials and recent studies assessing the benefits of anti-obesity medications in comorbid conditions such as type-2 diabetes mellitus, psychiatric disorders, cardiovascular diseases, hypertension, renal diseases, and liver diseases. This review briefly examines the aspects of recognizing and addressing iatrogenic weight gain; discusses the precautions and prescribing considerations of anti-obesity medications, including side effects and possible dose adjustments in various comorbid conditions; and provides an expert opinion on an individualized choice of the best anti-obesity medication.

Keywords: chronic illness; co-morbidities; complex; obesity; pharmacotherapy.

Publication types

  • Review

MeSH terms

  • Adult
  • Anti-Obesity Agents* / therapeutic use
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Life Style
  • Obesity / drug therapy
  • United States
  • Weight Gain

Substances

  • Anti-Obesity Agents